Abstract

We are attempting to develop novel agents that alter the biology of the cancer. In order to accomplish this goal, we have initiated a collaboration with a unique computational chemistry company to design compounds that abrogate key molecular targets in the development, progression and metastasis of cancer. These studies are just being initiated but could provide valuable new agents. A successful drug development program requires a complete understanding of the clinical pharmacology of the agent(s) being evaluated. One of our interests is to utilize pharmacokinetic/pharmacodynamic concepts in the development of novel anticancer agents. In addition, we routinely characterize the protein binding and metabolism of novel agents. This has led to attempts to optimize therapy through characterizing the pharmacogenetics of patients and appreciates for potential drug interactions. Agents that we have recently been involved with include: MS275, UCN01, perifosine, OSI774, depsipeptide, 17-DMAG, COL3, flavopiridol, phenylbutyrate, PSC833 and phenylacetate.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
Division of Basic Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC010547-01
Application #
6952166
Study Section
(CTB)
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2003
Total Cost
Indirect Cost

  Institution

Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code

  Publications

Dahut, William L; Madan, Ravi A; Karakunnel, Joyson J et al. (2013) Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int 111:1269-80
Russo, Andrea L; Jedlicka, Kimberly; Wernick, Meredith et al. (2009) Urine analysis and protein networking identify met as a marker of metastatic prostate cancer. Clin Cancer Res 15:4292-8
Miles, Robert J; Price, Douglas K; Figg, William D (2008) Temporal-mediated FGFR1 independence: implications for targeting candidate molecules in prostate cancer. Cancer Biol Ther 7:1180-1
Gulley, James L; Aragon-Ching, Jeanny B; Steinberg, Seth M et al. (2008) Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 180:1432-7;discussion 1437
Dahut, William L; Scripture, Charity; Posadas, Edwin et al. (2008) A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 14:209-14
Di Lorenzo, Giuseppe; Figg, William D; Fossa, Sophie D et al. (2008) Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study. Eur Urol :
Sharifi, Nima; Dahut, William L; Figg, William D (2008) Secondary hormonal therapy for prostate cancer: what lies on the horizon? BJU Int 101:271-4
Scher, Howard I; Halabi, Susan; Tannock, Ian et al. (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-59
Arlen, Philip M; Bianco, Fernando; Dahut, William L et al. (2008) Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol 179:2181-5;discussion 2185-6
Figg, William D; Li, Haiqing; Sissung, Tristan et al. (2007) Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int 99:1047-55

Showing the most recent 10 out of 25 publications